Abstract
In addition to being effective in depressive disorders, monoamine oxidase inhibitors (MAOIs) have been shown to be effective in controlled studies of patient with panic disorder with agoraphobia, social phobia, atypical depression or mixed anxiety and depression, bulimia, posttraumatic stress disorder (PTSD) and borderline personality disorder. Uncontrolled case reports have noted MAOI efficacy in obsessive-compulsive disorder (OCD), trichotillomania, dysmorphophobia and avoidant personality disorder. Reversible inhibitors of MAO-A (RIMAs) appear safer than the classical irreversible MAOIs since they have less potential to increase blood pressure. They have not been studied as yet, however, in most of the conditions responsive to MAOIs. If RIMAs are found effective in these disorders, they would probably achieve wider use than MAOIs because they are safer and tend to cause fewer side effects.
Original language | English (US) |
---|---|
Pages (from-to) | 29-34 |
Number of pages | 6 |
Journal | Acta Psychiatrica Scandinavica, Supplement |
Volume | 360 |
State | Published - 1990 |
Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Psychiatry and Mental health
- Neuroscience(all)
Cite this
Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders. / Liebowitz, M. R.; Hollander, Eric; Schneier, F.; Campeas, R.; Welkowitz, L.; Hatterer, J.; Fallon, B.
In: Acta Psychiatrica Scandinavica, Supplement, Vol. 360, 1990, p. 29-34.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders.
AU - Liebowitz, M. R.
AU - Hollander, Eric
AU - Schneier, F.
AU - Campeas, R.
AU - Welkowitz, L.
AU - Hatterer, J.
AU - Fallon, B.
PY - 1990
Y1 - 1990
N2 - In addition to being effective in depressive disorders, monoamine oxidase inhibitors (MAOIs) have been shown to be effective in controlled studies of patient with panic disorder with agoraphobia, social phobia, atypical depression or mixed anxiety and depression, bulimia, posttraumatic stress disorder (PTSD) and borderline personality disorder. Uncontrolled case reports have noted MAOI efficacy in obsessive-compulsive disorder (OCD), trichotillomania, dysmorphophobia and avoidant personality disorder. Reversible inhibitors of MAO-A (RIMAs) appear safer than the classical irreversible MAOIs since they have less potential to increase blood pressure. They have not been studied as yet, however, in most of the conditions responsive to MAOIs. If RIMAs are found effective in these disorders, they would probably achieve wider use than MAOIs because they are safer and tend to cause fewer side effects.
AB - In addition to being effective in depressive disorders, monoamine oxidase inhibitors (MAOIs) have been shown to be effective in controlled studies of patient with panic disorder with agoraphobia, social phobia, atypical depression or mixed anxiety and depression, bulimia, posttraumatic stress disorder (PTSD) and borderline personality disorder. Uncontrolled case reports have noted MAOI efficacy in obsessive-compulsive disorder (OCD), trichotillomania, dysmorphophobia and avoidant personality disorder. Reversible inhibitors of MAO-A (RIMAs) appear safer than the classical irreversible MAOIs since they have less potential to increase blood pressure. They have not been studied as yet, however, in most of the conditions responsive to MAOIs. If RIMAs are found effective in these disorders, they would probably achieve wider use than MAOIs because they are safer and tend to cause fewer side effects.
UR - http://www.scopus.com/inward/record.url?scp=0025616984&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025616984&partnerID=8YFLogxK
M3 - Article
C2 - 2248064
AN - SCOPUS:0025616984
VL - 360
SP - 29
EP - 34
JO - Acta Psychiatrica Scandinavica, Supplement
JF - Acta Psychiatrica Scandinavica, Supplement
SN - 0065-1591
ER -